Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol

Faouzi Djebbari, Nicola Stoner, Verna Lavender

Recent advances in cancer therapeutics have resulted in significantly improved overall survival and progression-free survival for patients. Targeted oral systemic anticancer therapies (SACT) offer a range of treatment approaches that differ from traditional cytotoxic chemotherapy: non-cytotoxic oral SACT target malignant disease continuously, have less broad and more favourable safety profiles, which can improve patients' quality of life (QoL). Toxicities associated with daily oral SACT administration can, however, result in non-adherence and a reduced QoL. Non-conventional dosing of oral SACT, where unlicensed doses/schedules of drugs are prescribed, is one approach increasingly adopted by clinicians to reduce toxicities and subsequent non-adherence and to improve QoL. Guidance governing this practice is, however, limited. This systematic review aims to identify evidence about prescribing practices of, and outcomes from, non-conventional dosing of oral SACT in oncology and malignant haematology. A search using the following electronic databases will be conducted: Ovid MEDLINE, Ovid EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Registry of Controlled Trials. Studies will be selected based on predefined inclusion/exclusion criteria. Critical appraisal will be conducted to identify potential biases, strengths and limitations of included studies. Extracted data will be tabulated to sort and summarise key findings. An initial literature search indicated that studies reporting non-standard dosing of oral SACT intervention studies are diverse and heterogeneous in study design. Extracted data will, therefore, be tabulated, and together with a narrative synthesis of integrated key findings, will be presented and discussed in reference to the strengths and weaknesses of the evidence base. If sufficient stratified data is available (e.g. age group, tumour type, disease stage) or intervention (drug, dosing schedule), sub-group analysis will be conducted to inform prescribing practice. This review will identify relevant literature on the topic to inform prescribers working in oncology and malignant haematology. It will also analyse any evidence of the following outcomes: toxicity, treatment adherence and/or QoL outcomes for patients receiving non-standard doses of oral SACT. Limitations in the evidence base may arise from variability in both the type and quality of studies reviewed. PROSPERO CRD42017076195 .